Follistatin-like 1 (Fstl1), also known as transforming growth factor-betaÀstimulated clone 36, is an extra-cellular glycoprotein that was originally cloned from a mouse osteoblastic cell line as a transforming growth factor-betaÀinducible gene and is highly conserved across species (8) . Fstl1 acts in a noncanonical manner relative to other follistatin family members. However, its functions remain poorly understood and are possibly cell-type specific.
Transduction of Fstl1 into cancer cell lines suppresses growth and invasion (9) . Fstl1 is reported to have both anti-inflammatory (10) and proinflammatory (11) actions. Recent studies also implicate Fstl1 in the pathophysiology of cardiac disease in several murine models. Fstl1 overexpression minimized ischemiareperfusion injury and diminished apoptosis (12) .
Similarly, Fstl1 improved endothelial cell function and revascularization in a hind-limb ischemia model (13) . Recently, we demonstrated elevated blood levels of Fstl1 in a cohort of humans with chronic, stable HFrEF; where elevated Fstl1 levels were significantly associated with LV mass and circulating brain natriuretic peptide (BNP) levels, suggesting a pathogenic role for Fstl1 in cardiac remodeling and LVH (14) . In patients with HFpEF, more often than not, structural changes such as LVH are present, because HTN is a major risk factor for the development of LVH (1) .
We previously utilized a murine model of HFpEF, which demonstrates features consistent with HFpEF in humans (15) (16) (17) . HFpEF mice exhibit exercise Real-Time Micro Visualization 707B Scanhead (VisualSonic Inc., Toronto, Ontario, Canada), as previously described (16) . Briefly, to assess diastolic function, mice were anesthetized with isoflurane (0.5% for induction followed by 0.5% to 1.5% for maintenance) and maintained at an HR of w350 beats/min, because diastolic function is sensitive to HR and loading conditions. The maximum dose of isoflurane had minimal effects on diastolic function (16, 19) . Pulse wave measurements were recorded.
Interventricular septum wall thickness (IVST), LV posterior wall thickness (LVPWT), LV end-diastolic diameter (LVEDD), LV end-systolic diameter, and LVEF were obtained. Total wall thickness was derived from an average of the IVST and LVPWT. LV mass was calculated using the formula: LV mass
, as described by Kiatchoosakun et al. (20) . After these measurements, mice were sacrificed, and the ratio of wet to dry lung weight was used as an indicator of pulmonary congestion.
A d e n o v i r a l v e c t o r e x p e r i m e n t s . and myocardial fibrosis as previously described (16) .
These sections were analyzed, blinded to group identity. Fstl1 staining was assessed as previously described (18) . Digital images of stained sections were acquired using an Olympus BX41 Clinical Microscope (Olympus America Inc., Center Valley, Pennsylvania) and analyzed using ImageJ (National Institutes of Health, Bethesda, Maryland).
R N A i s o l a t i o n a n d q u a n t i t a t i v e r e a l -t i m e P C R . Total RNA was extracted, and cDNA was synthesized as previously described (16 Primer sequences are shown in Table 1 .
W e s t e r n b l o t a n a l y s i s . Protein extraction and western blot analysis were performed as described previously (16, 22) . STATISTICAL ANALYSIS. Statistical significance of differences between the 2 groups was assessed by 2-tailed unpaired Student t tests. One-way ANOVA and the Newman-Keuls post-hoc test were used to test for differences among at least 3 groups. In cases where the data was not normally distributed, a Kruskal-Wallis test followed by a Dunn test was used.
A p value #0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc. La Jolla, California). 
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Tanaka et al. Tanaka et al. Treatment with Ad-Fstl1 significantly reduced cardiac hypertrophy in HFpEF, as assessed by the heart weight to body weight ratio, when compared with Adbgal (4.75 AE 0.04 mg/g vs. 5.27 AE 0.17 mg/g; p < 0.01).
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Ad-Fstl1 had no effect on heart weight in salineinfused mice (4.17 AE 0.04 mg/g vs. Ad-bgal: 3.90 AE 0.05 mg/g; p ¼ NS) ( Figure 3A) . Treatment with Ad-Fstl1 also ameliorated a measure of diastolic dysfunction.
The E/A ratio was significantly reduced with Ad-Fstl1
(1.88 AE 0.10 vs. Ad-bgal: 1.50 AE 0.10; p < 0.05) ( Figure 3B ). Taken together, these data indicate that treatment with Fstl1 reduces aldosterone-induced cardiac hypertrophy both in vitro and in vivo. In concert with the decreased LVH, the reduced E/A ratio also suggests an improvement in diastolic dysfunction. Table 3 .
Body weight was comparable between all experimental groups. Systolic BP was measured weekly 
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Tanaka et al. Table 3) .
As expected, chronic aldosterone infusion caused
HFpEF and resulted in cardiac hypertrophy, as Statistical analysis by analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests. Abbreviations as in Figure 1 . A ¼ peak late transmitral flow velocity; cFstl1-KO ¼ follistatin-like 1 cardiac myocyte-specific knockout; DT ¼ early filling deceleration time; E ¼ peak early transmitral flow velocity; e 0 ¼ peak early diastolic mitral annular velocity; E/A ¼ the ratio of peak E velocity to peak A velocity; IVRT ¼ isovolumetric relaxation time; TWT ¼ total wall thickness; WT ¼ wild-type; other abbreviations as in Table 2 . 
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Fstl1 and LVH in HFpEF
measured by an increase in the heart weight to body weight ratio, in WT mice versus respective saline-infusion control mice (5.56 AE 0.14 mg/g vs. 4.46 AE 0.11 mg/g; p < 0.0001). Cardiac hypertrophy was, however, greater in cFstl1-KO mice with HFpEF (6.14 AE 0.23 mg/g) than in WT-HFpEF mice (p < 0.05) ( Figure 4B ). Consistent with these findings, total wall thickness, determined by echocardiography, was also increased in both groups of aldosterone-infused mice, but increased more in cFstl1-KO-HFpEF than WTHFpEF. There were no differences in LVEDD and LV end-systolic diameter between the experimental groups of mice ( Table 3) .
Both WT-HFpEF and cFstl1-KO-HFpEF mice had a normal LVEF but demonstrated pulmonary congestion. However, there was more lung congestion in cFstl1-KO-HFpEF than WT-HFpEF mice, as measured by an increase in the wet-to-dry lung weight ratio (4.57 AE 0.07 vs. 4.37 AE 0.05; p < 0.01) ( Figure 4C ). Figure 4D ) showed an increased peak E-wave velocity in both groups of HFpEF mice (p < 0.01 vs. respective sham groups).
Mitral Doppler analysis (Table 3,
The peak E-wave velocity in cFstl1-KO-HFpEF mice was, however, significantly higher than in WTHFpEF mice (p < 0.05). Because the peak A-wave velocity remained comparable in all groups of mice, the resultant E/A ratio was higher in aldosterone- LVH regression is not always accompanied by improvement in parameters of diastolic dysfunction (52) , and conversely, improvement in diastolic dysfunction parameters is not consistently accompanied by LVH regression (15) . In the present study, mice with HFpEF, that lack cardiac myocyte-specific Fstl1 showed exacerbation of LVH that was accompanied by worsening of diastolic dysfunction.
Fstl1 displays a Janus-like role in inflammation.
Pro-inflammatory actions of Fstl1 are seen in several chronic disorders such as rheumatoid arthritis, ulcerative colitis, and obesity (11, 53, 54) . Conversely the anti-inflammatory role of Fstl1 has also been described in vascular, myocardial, and renal injury models (26, 41, 42 
